Open access chemical probes for epigenetic targets

Future Medicinal Chemistry

Volumn 7, Issue 14, 2015, Pages 1901-1917

  Brown, Peter J ^a   Müller, Susanne ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; BROMODOMAIN INHIBITOR; PROTEIN METHYLTRANSFERASE; HISTONE DEMETHYLASE; MOLECULAR LIBRARY; NUCLEAR PROTEIN;

DRUG INDUSTRY; EPIGENETICS; GENE TARGETING; HUMAN; MOLECULAR PROBE; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHEMISTRY; DRUG DEVELOPMENT; METABOLISM; MOLECULAR DOCKING; MOLECULAR LIBRARY; PHYLOGENY; RNA INTERFERENCE;

BINDING SITES; DRUG DISCOVERY; EPIGENOMICS; HISTONE DEMETHYLASES; MOLECULAR DOCKING SIMULATION; NUCLEAR PROTEINS; PHYLOGENY; PROTEIN METHYLTRANSFERASES; RNA INTERFERENCE; SMALL MOLECULE LIBRARIES;

EID: 84945312166     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.15.127     Document Type: Review

References (111)

1. Holliday R. Epigenetics: a historical overview. Epigenetics. 1(2), 76-80 (2006
2. Wongtrakoongate P. Epigenetic therapy of cancer stem and progenitor cells by targeting DNA methylation machineries. World J. Stem Cells. 7(1), 137-148 (2015
3. Lin S, Gregory RI. MicroRNA biogenesis pathways in cancer. Nat. Rev. Cancer. 15(6), 321-333 (2015
4. Devaux Y, Zangrando J, Schroen B, et al. Long noncoding RNAs in cardiac development and ageing. Nat. Rev. Cardiol. doi:10.1038/nrcardio.2015.55 (2015) (Epub ahead of print
5. Velagapudi SP, Vummidi BR, Disney MD. Small molecule chemical probes of microRNA function. Curr. Opin. Chem. Biol. 24, 97-103 (2015
6. Tessarz P, Kouzarides T. Histone core modifications regulating nucleosome structure and dynamics. Nat. Rev. Mol. Cell Biol. 15(11), 703-708 (2014
7. Muller S, Brown PJ. Epigenetic chemical probes. Clin. Pharmacol. Ther. 92(6), 689-693 (2012
8. Zwergel C, Valente S, Jacob C, Mai A. Emerging approaches for histone deacetylase inhibitor drug discovery. Expert Opin. Drug Discov. 10(6), 599-613 (2015
9. Castronovo V, Peixoto P, Bellahcene A, Turtoi A. Histone deacetylases and cancer-Associated angiogenesis: current understanding of the biology and clinical perspectives. Crit. Rev. Oncog. 20(1-2), 119-137 (2015
10. Filippakopoulos P, Picaud S, Mangos M, et al. Histone recognition and large-scale structural analysis of the human bromodomain family. Cell. 149(1), 214-231 (2012
11. Filippakopoulos P, Knapp S. Targeting bromodomains: epigenetic readers of lysine acetylation. Nat. Rev. Drug Discov. 13(5), 337-356 (2014
12. Weiss WA, Taylor SS, Shokat KM. Recognizing and exploiting differences between RNAi and small-molecule inhibitors. Nat. Chem. Biol. 3(12), 739-744 (2007
13. Frye SV. The art of the chemical probe. Nat. Chem. Biol. 6(3), 159-161 (2010
14. Workman P, Collins I. Probing the probes: fitness factors for small molecule tools. Chem. Biol. 17(6), 561-577 (2010
15. Bunnage ME. Getting pharmaceutical R&D back on target. Nat. Chem. Biol. 7(6), 335-339 (2011
16. SGC. Epigenetics Probes Collection. www.thesgc.org
17. CEREP. ExpresSProfile. www.cerep.fr
18. Weigelt J. The case for open-Access chemical biology. A strategy for pre-competitive medicinal chemistry to promote drug discovery. EMBO Rep. 10(9), 941-945 (2009
19. Edwards AM, Bountra C, Kerr DJ, Willson TM. Open access chemical and clinical probes to support drug discovery. Nat. Chem. Biol. 5(7), 436-440 (2009
20. National Cancer Institute. NCI Drug Dictionary. www.cancer.gov
21. Berkovits BD, Wolgemuth DJ. The role of the double bromodomain-containing BET genes during mammalian spermatogenesis. Curr. Top. Dev. Biol. 102, 293-326 (2013
22. Chung CW. Small molecule bromodomain inhibitors: extending the druggable genome. Prog. Med. Chem. 51, 1-55 (2012
23. Filippakopoulos P, Knapp S. The bromodomain interaction module. FEBS Lett. 586(17), 2692-2704 (2012
24. Muller S, Filippakopoulos P, Knapp S. Bromodomains as therapeutic targets. Expert Rev. Mol. Med. 13, e29 (2011
25. Sanchez R, Meslamani J, Zhou MM. The bromodomain: from epigenome reader to druggable target. Biochim. Biophys. Acta 1839(8), 676-685 (2014
26. Shi J, Vakoc CR. The mechanisms behind the therapeutic activity of BET bromodomain inhibition. Mol. Cell. 54(5), 728-736 (2014
27. Huang B, Yang XD, Zhou MM, Ozato K, Chen LF. Brd4 coactivates transcriptional activation of NF-kappaB via specific binding to acetylated RelA. Mol. Cell. Biol. 29(5), 1375-1387 (2009
28. Stewart HJ, Horne GA, Bastow S, Chevassut TJ. BRD4 Associates with p53 in DNMT3A-mutated Leukemia Cells and Is Implicated in Apoptosis by the Bromodomain Inhibitor JQ1. Cancer Med. 2(6), 826-835 (2013
29. Asangani IA, Dommeti VL, Wang X, et al. Therapeutic targeting of BET bromodomain proteins in castrationresistant prostate cancer. Nature. 510(7504), 278-282 (2014
30. Palermo RD, Webb HM, West MJ. RNA polymerase II stalling promotes nucleosome occlusion and pTEFb recruitment to drive immortalization by Epstein-Barr virus. PLoS Pathog. 7(10), e1002334 (2011
31. Gupta SS, Maetzig T, Maertens GN, et al. Bromo- And extraterminal domain chromatin regulators serve as cofactors for murine leukemia virus integration. J. Virol. 87(23), 12721-12736 (2013
32. Wang X, Helfer CM, Pancholi N, Bradner JE, You J. Recruitment of Brd4 to the human papillomavirus type 16 DNA replication complex is essential for replication of viral DNA. J. Virol. 87(7), 3871-3884 (2013
33. Anders L, Guenther MG, Qi J, et al. Genome-wide localization of small molecules. Nat. Biotechnol. 32(1), 92-96 (2014
34. Winter GE, Buckley DL, Paulk J, et al. Drug development. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science. 348(6241), 1376-1381 (2015
35. Muller S, Lingard H, Knapp S. Selective Targeting of Protein Interactions Mediated by BET Bromodomains. Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany (2014
36. Fu LL, Tian M, Li X, et al. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery. Oncotarget. 6(8), 5501-5516 (2015
37. Brand M, Measures AM, Wilson BG, et al. Small molecule inhibitors of bromodomain-Acetyl-lysine interactions. ACS Chem. Biol. 10(1), 22-39 (2015
38. Gallenkamp D, Gelato KA, Haendler B, Weinmann H. Bromodomains and their pharmacological inhibitors. ChemMedChem. 9(3), 438-464 (2014
39. Tang Y, Gholamin S, Schubert S, et al. Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. Nat. Med. 20(7), 732-740 (2014
40. Kalkhoven E. CBP and p300: HATs for different occasions. Biochem. Pharmacol. 68(6), 1145-1155 (2004
41. Philpott M, Yang J, Tumber T, et al. Bromodomain-peptide displacement assays for interactome mapping and inhibitor discovery. Mol. Biosyst. 7(10), 2899-2908 (2011
42. Hay DA, Fedorov O, Martin S, et al. Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains. J. Am. Chem. Soc. 136(26), 9308-9319 (2014
43. Das C, Roy S, Namjoshi S, et al. Binding of the histone chaperone ASF1 to the CBP bromodomain promotes histone acetylation. Proc. Natl Acad. Sci. USA. 111(12), E1072-E1081 (2014
44. Giotopoulos G, Chan WI, Horton SJ, et al. The epigenetic regulators CBP and p300 facilitate leukemogenesis and represent therapeutic targets in acute myeloid leukemia. Oncogene doi:10.1038/onc.2015.92 (2015) (Epub ahead of print
45. Thanasopoulou A, Dumrese K, Picaud S, Fedorov O, Knapp S, Schwaller J. Targeting aberrant self-renewal of leukemic cells with a novel CBP/p300 bromodomain inhibitor. Blood. 124(21), 3750-3750 (2014
46. Hammitzsch A, Tallant C, Fedorov O, et al. CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses. Proc. Natl Acad. Sci. USA. 112(34), 10763-10773 (2015
47. Roe JS, Mercan F, Rivera K, Pappin DJ, Vakoc CR. BET bromodomain inhibition suppresses the function of hematopoietic transcription factors in acute myeloid leukemia. Mol. Cell doi:10.1016/j.molcel.2015.04.011 (2015) (Epub ahead of print
48. Son EY, Crabtree GR. The role of BAF (mSWI/SNF) complexes in mammalian neural development. Am. J. Med. Genet. C Semin. Med. Genet. 166C(3), 333-349 (2014
49. Middeljans E, Wan X, Jansen PW, Sharma V, Stunnenberg HG, Logie C. SS18 together with animal-specific factors defines human BAF-Type SWI/SNF complexes. PLoS ONE. 7(3), e33834 (2012
50. Helming KC, Wang X, Roberts CW. Vulnerabilities of mutant SWI/SNF complexes in cancer. Cancer Cell. 26(3), 309-317 (2014
51. Benusiglio PR, Couve S, Gilbert-Dussardier B, et al. A germline mutation in PBRM1 predisposes to renal cell carcinoma. J. Med. Genet. 52(6), 426-430 (2015
52. Kim JY, Lee SH, Moon KC, et al. The impact of PBRM1 expression on prognostic and predictive marker in metastatic renal cell carcinoma. J. Urol. doi:10.1016/j.juro.2015.04.114 (2015) (Epub ahead of print
53. Hohmann AF, Vakoc CR. A rationale to target the SWI/SNF complex for cancer therapy. Trends Genet. 30(8), 356-363 (2014
54. Scotto L, Narayan G, Nandula SV, et al. Integrative genomics analysis of chromosome 5p gain in cervical cancer reveals target over-expressed genes, including Drosha. Mol. Cancer 7, 58 (2008
55. Chiu YH, Lee JY, Cantley LC. BRD7, a tumor suppressor, interacts with p85alpha and regulates PI3K activity. Mol. Cell. 54(1), 193-202 (2014
56. Clark PG, Vieira LC, Tallant C, et al. LP99: discovery and synthesis of the first selective BRD7/9 bromodomain inhibitor. Angew. Chem. Int. Ed. Engl. 54(21), 6217-6221 (2015
57. Drost J, Mantovani F, Tocco F, et al. BRD7 is a candidate tumour suppressor gene required for p53 function. Nat. Cell Biol. 12(4), 380-389 (2010
58. SGC. BI-9564 - A chemical probe for BRD9 and BRD7. www.thesgc.org/chemical-probes/bi-9564
59. Theodoulou NH, Bamborough P, Bannister AJ, et al. Discovery of I-BRD9, a selective cell active chemical probe for bromodomain containing protein 9 inhibition. J. Med. Chem. doi:10.1021/acs.jmedchem.5b00256 (2015) (Epub ahead of print
60. Medzhitov R, Horng T. Transcriptional control of the inflammatory response. Nat. Rev. Immunol. 9(10), 692-703 (2009
61. SGC. www.thesgc.org/chemical-probes/pfi-3
62. Fedorov O, Castex J, Tallant C, et al. Selective targeting of the BRG/PB1 bromodomains impairs embryonic and trophoblast stem cells maintenance. Science Advances (2015) (In Press
63. Avvakumov N, Cote J, The MYST family cancer of histone acetyltransferases and their intimate links to cancer. Oncogene. 26(7), 5395-5407 (2007
64. Paggetti J, Largeot A, Aucagne R, et al. Crosstalk between leukemia-Associated proteins MOZ and MLL regulates HOX gene expression in human cord blood CD34+ cells. Oncogene. 29(36), 5019-5031 (2010
65. Sheikh BN, Downer NL, Phipson B, et al. MOZ and BMI1 play opposing roles during Hox gene activation in ES cells and in body segment identity specification in vivo. Proc. Natl Acad. Sci. USA. 112(17), 5437-5442 (2015
66. Laue K, Daujat S, Crump JG, et al. The multidomain protein Brpf1 binds histones and is required for Hox gene expression and segmental identity. Development. 135(11), 1935-1946 (2008
67. You L, Yan K, Zhou J, et al. The lysine acetyltransferase activator Brpf1 governs dentate gyrus development through neural stem cells and progenitors. PLoS Genet. 11(3), e1005034 (2015
68. Mishima Y, Wang C, Miyagi S, et al. Histone acetylation mediated by Brd1 is crucial for Cd8 gene activation during early thymocyte development. Nat. Commun. 5, 5872 (2014
69. Mishima Y, Miyagi S, Saraya A, et al. The Hbo1-Brd1/Brpf2 complex is responsible for global acetylation of H3K14 and required for fetal liver erythropoiesis. Blood. 118(9), 2443-2453 (2011
70. SGC. OF-1 - A chemical probe for BRPF bromodomains. www.thesgc.org/chemical-probes/of-1
71. SGC. NI-57 - A chemical probe for BRPF bromodomains. www.thesgc.org/chemical-probes/ni-57
72. SGC. PFI-4 - A chemical probe for BRPF1B. www.thesgc.org/chemical-probes/pfi-4
73. Bennett J, Fedorov O, Tallant C, et al. Discovery of a chemical tool inhibitor targeting the bromodomains of TRIM24 and BRPF. J. Med. Chem. doi:10.1021/acs.jmedchem.5b00458 (2015) (Epub ahead of print
74. Palmer WS, Poncet-Montange G, Liu G, et al. Structureguided design of IACS-9571, a selective high-Affinity dual TRIM24-BRPF1 bromodomain inhibitor. J. Med. Chem. doi:10.1021/acs.jmedchem.5b00405 (2015) (Epub ahead of print
75. Kruidenier L, Chung CW, Cheng Z, et al. A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature. 488(7411), 404-408 (2012
76. SGC. GSK-J1: an inhibitor for human H3K27me3 and H3K4me3/2/1 demethylases. www.thesgc.org/chemical-probes/gskj1
77. Swigut T, Wysocka J. H3K27 demethylases, at long last. Cell. 131(1), 29-32 (2007
78. Liu Z, Cao W, Xu L, et al. The histone H3 lysine-27 demethylase Jmjd3 plays a critical role in specific regulation of Th17 cell differentiation. J. Mol. Cell. Biol. doi:10.1093/jmcb/mjv022 (2015) (Epub ahead of print
79. Messer HG, Jacobs D, Dhummakupt A, Bloom DC. Inhibition of H3K27me3-specific histone demethylases JMJD3 and UTX blocks reactivation of herpes simplex virus 1 in trigeminal ganglion neurons. J. Virol. 89(6), 3417-3420 (2015
80. Ntziachristos P, Tsirigos A, Welstead GG, et al. Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia. Nature. 514(7523), 513-517 (2014
81. Hashizume R, Andor N, Ihara Y, et al. Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma. Nat. Med. 20(12), 1394-1396 (2014
82. Grasso CS, Tang Y, Truffaux N, et al. Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nat. Med. 21(6), 555-559 (2015
83. Kubicek S, O'Sullivan RJ, August EM, et al. Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol. Cell. 25(3), 473-481 (2007
84. Vedadi M, Barsyte-Lovejoy D, Liu F, et al. A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nat. Chem. Biol. 7(8), 566-574 (2011
85. Liu F, Barsyte-Lovejoy D, Li F, et al. Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP. J. Med. Chem. 56(21), 8931-8942 (2013
86. Ling BM, Gopinadhan S, Kok WK, et al. G9a mediates Sharp-1-dependent inhibition of skeletal muscle differentiation. Mol. Biol. Cell. 23(24), 4778-4785 (2012
87. Ohno H, Shinoda K, Ohyama K, Sharp LZ, Kajimura S. EHMT1 controls brown adipose cell fate and thermogenesis through the PRDM16 complex. Nature. 504(7478), 163-167 (2013
88. Lehnertz B, Pabst C, Su L, et al. The methyltransferase G9a regulates HoxA9-dependent transcription in AML. Genes Dev. 28(4), 317-327 (2014
89. Sweis RF, Pliushchev M, Brown PJ, et al. Discovery and development of potent and selective inhibitors of histone methyltransferase g9a. ACS Med. Chem. Lett. 5(2), 205-209 (2014
90. Mcginty RK, Kim J, Chatterjee C, Roeder RG, Muir TW. Chemically ubiquitylated histone H2B stimulates hDot1Lmediated intranucleosomal methylation. Nature. 453(7196), 812-816 (2008
91. Yu W, Smil D, Li F, et al. Bromo-deaza-SAH: a potent and selective DOT1L inhibitor. Bioorg. Med. Chem. 21(7), 1787-1794 (2013
92. Daigle SR, Olhava EJ, Therkelsen CA, et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell. 20(1), 53-65 (2011
93. Basavapathruni A, Jin L, Daigle SR, et al. Conformational adaptation drives potent, selective and durable inhibition of the human protein methyltransferase DOT1L. Chem. Biol. Drug Des. 80(6), 971-980 (2012
94. Yu W, Chory EJ, Wernimont AK, et al. Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors. Nat. Commun. 3 1288 (2012
95. Wigle TJ, Knutson SK, Jin L, et al. The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states. FEBS Lett. 585(19), 3011-3014 (2011
96. Verma SK, Tian X, Lafrance LV, et al. Identification of potent, selective, cell-Active inhibitors of the histone lysine methyltransferase EZH2. ACS Med. Chem. Lett. 3(12), 1091-1096 (2012
97. Knutson SK, Wigle TJ, Warholic NM, et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat. Chem. Biol. 8(11), 890-896 (2012
98. Konze KD, Ma A, Li F, et al. An orally bioavailable chemical probe of the lysine methyltransferases EZH2 and EZH1. ACS Chem. Biol. 8(6), 1324-1334 (2013
99. Campaner S, Spreafico F, Burgold T, et al. The methyltransferase Set7/9 (Setd7) is dispensable for the p53-mediated DNA damage response in vivo. Mol. Cell. 43(4), 681-688 (2011
100. Liu X, Wang D, Zhao Y, et al. Methyltransferase Set7/9 regulates p53 activity by interacting with Sirtuin 1 (SIRT1). Proc. Natl Acad. Sci. USA. 108(5), 1925-1930 (2011
101. Oudhoff MJ, Freeman SA, Couzens AL, et al. Control of the hippo pathway by Set7-dependent methylation of Yap. Dev. Cell. 26(2), 188-194 (2013
102. Barsyte-Lovejoy D, Li F, Oudhoff MJ, et al. (R)-PFI-2 is a potent and selective inhibitor of SETD7 methyltransferase activity in cells. Proc. Natl Acad. Sci. USA. 111(35), 12853-12858 (2014
103. Cho H, Herzka T, Zheng W, et al. RapidCaP, a novel GEM model for metastatic prostate cancer analysis and therapy, reveals myc as a driver of Pten-mutant metastasis. Cancer Discov. 4(3), 318-333 (2014
104. Saddic LA, West LE, Aslanian A, et al. Methylation of the retinoblastoma tumor suppressor by SMYD2. J. Biol. Chem. 285(48), 37733-37740 (2010
105. Huang J, Perez-Burgos L, Placek BJ, et al. Repression of p53 activity by Smyd2-mediated methylation. Nature. 444(7119), 629-632 (2006
106. Ferguson AD, Larsen NA, Howard T, et al. Structural Basis of Substrate Methylation and Inhibition of SMYD2. Structure. 19(9), 1262-1273 (2011
107. Nguyen H, Allali-Hassani A, Antonysamy S, et al. LLY-507, a cell-Active, potent, and selective inhibitor of proteinlysine methyltransferase SMYD2. J. Biol. Chem. 290(22), 13641-13653 (2015
108. Kaniskan HU, Szewczyk MM, Yu Z, et al. A potent, selective and cell-Active allosteric inhibitor of protein arginine methyltransferase 3 (PRMT3). Angew. Chem. Int. Ed. Engl. 54(17), 5166-5170 (2015
109. James LI, Barsyte-Lovejoy D, Zhong N, et al. Discovery of a chemical probe for the L3MBTL3 methyllysine reader domain. Nat. Chem. Biol. 9(3), 184-191 (2013
110. Senisterra G, Wu H, Allali-Hassani A, et al. Small-molecule inhibition of MLL activity by disruption of its interaction with WDR5. Biochem. J. 449(1), 151-159 (2013
111. Grebien F, Vedadi M, Getlik M, et al. Pharmacological targeting of the Wdr5-MLL interaction in C/EBPalpha N-Terminal leukemia. Nat. Chem. Biol. 11(8), 571-578 (2015